Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.
This feature in TOP aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. This issue is focused on sarcomas, the July cancer awareness month. Healthcare practitioners may use this listing in discussions with their patients to encourage enrollment. As NCCN has stated, “The best management of any cancer patient is in a clinical trial.”
These clinical trial listings can be found at www.ClinicalTrials.gov.
- Phase II Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)
- ClinicalTrials.gov identifier: NCT06436612
- Sponsor: Jonsson Comprehensive Cancer Center
- Contacts: Christy Palodichuk, 310-794-2971; Vincent Basehart, 310-267-8954
- Prospective Observational Trial of Two Neoadjuvant Hypofractionated Radiotherapy Regimens Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT04506008
- Sponsor: Vanderbilt-Ingram Cancer Center
- Principal Investigator/Contact: Eric Shinohara, MD, Vanderbilt Medical Center, 713-792-3626
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- ClinicalTrials.gov identifier: NCT07193550
- Sponsor: M.D. Anderson Cancer Center
- Collaborator: Exelixis
- Principal Investigator: John Livingston, MD, M.D. Anderson Cancer Center
- URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas
- ClinicalTrials.gov identifier: NCT07089992
- Sponsor: Memorial Sloan Kettering Cancer Center
- Principal Investigator/Contact: Robert Maki, MD, MPH, Memorial Sloan Kettering Cancer Center, 646-888-5059
- Collaborator: Merck Sharp & Dohme LLC
- Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
- ClinicalTrials.gov identifier: NCT07602777
- Sponsor: GlaxoSmithKline
- Contacts: US GSK Clinical Trials Call Center, 877-379-3718; EU GSK Clinical Trials Call Center, +44 (0) 20 89904466
- A Phase II Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas
- ClinicalTrials.gov identifier: NCT07014137
- Sponsor: University Health Network, Toronto
- Contact: Albiruni Razak, MD, 416-586-5371
- A Multi-cohort Study of Retifanlimab With or Without Gemcitabine and Docetaxel in Patients With Advanced Sarcoma
- ClinicalTrials.gov identifier: NCT04577014
- Sponsor: Memorial Sloan Kettering Cancer Center
- Collaborator: Incyte Corporation
- Contacts: Sandra D'Angelo, MD, 646-888-4159; William Tap, MD, 646-888-4163
- GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced Sarcoma
- ClinicalTrials.gov identifier: NCT04535713
- Sponsor: Sarcoma Oncology Research Center, LLC
- Principal Investigator/Contact: Sant P Chawla, MD, Sarcoma Oncology Research Center, LLC, 310-552-9999
- The TNT Protocol: A Phase 2 Study Using Talimogene Laherparepvec,Nivolumab and Trabectedin as First, Second/Third Line Therapy for Advanced Sarcoma, Including Desmoid Tumor and Chordoma
- ClinicalTrials.gov identifier: NCT03886311
- Sponsor: Sarcoma Oncology Research Center, LLC
- Principal Investigator/Contact: Sant P Chawla, MD, Sarcoma Oncology Center, 310-552-9999
- SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
- ClinicalTrials.gov identifier: NCT07650656
- Sponsor: City of Hope Medical Center
- Collaborator: National Cancer Institute (NCI)
- Principal Investigator: Thinzar Lwin, City of Hope Medical Center
- Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT07291297
- Sponsor: Wake Forest University Health Sciences
- Collaborators: Atrium Health Levine Cancer Institute; Paula Takacs Foundation
- A Phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma of Soft Tissue
- ClinicalTrials.gov identifier: NCT07125183
- Sponsor: University of Colorado, Denver
- Collaborators: Cancer League of Colorado
- Contact: Chelsey Cartwright, 720-848-0741
- A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- ClinicalTrials.gov identifier: NCT05734066
- Sponsor: Jazz Pharmaceuticals
- Contact: Clinical Trial Disclosure & Transparency, 215-832-3750
- Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma: A Single Institution Phase II Trial
- ClinicalTrials.gov identifier: NCT06905132
- Sponsor: Medical University of South Carolina
- Principal Investigator: Jennifer Harper, MD, Medical University of South Carolina
- Contact: HCC Clinical Trials Office, 843-792-9321
- Phase 2 5-Day Preoperative Radiation for Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT06087861
- Sponsor: Stanford University
- Contacts: Alyssa Yauger, 650-498-5271; Aastha Dubey, 650-725-2084
- A Multicenter Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Adults
- ClinicalTrials.gov identifier: NCT06445166
- Sponsor: Washington University School of Medicine
- Collaborator: The Foundation for Barnes-Jewish Hospital
- Principal Investigator/Contact: Lee Ratner, MD, PhD, Washington University School of Medicine, 314-362-8836
- A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
- ClinicalTrials.gov identifier: NCT06797999
- Sponsor: Adcendo ApS
- Contacts: René Smrčka, +45 3144 0653; Margaret McNaull, +44 7818 457619
- A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall
- ClinicalTrials.gov identifier: NCT05755113
- Sponsor: QBiotics Group Limited
- Principal Investigator:Edmund Bartlett, MD,Memorial Sloan Kettering Cancer Center